The United Kingdom and the United States have secured a key trade agreement that will ensure no tariffs on British medicine shipments being sold in the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that tariffs on these key products will stay at nothing for a timeframe of 36 months.
This deal follows recent statements to significantly raise duties on branded pharmaceutical products, with figures discussed reaching double the cost.
"This agreement with the Britain strengthens the global environment for innovative medicines and introduces long-overdue balance to transatlantic drug exports," a release noted.
Economic Importance
Medicines constitute one of the the United Kingdom's biggest exports to the America, which is easily the primary market for large UK drugmakers.
Statistics reveal that in the year prior to last September, the UK sold pharmaceutical products worth £11.1bn to the US. This value made up a significant portion of total UK exports in that span.
"This deal protects jobs, boosts funding and sets the stage for the UK to emerge as a worldwide center for life sciences," a government official remarked.
Specific UK Commitments
The deal entails several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to increase overall NHS spending on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum manufacturers must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, rebates exceeded twenty percent.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
This friction were intensified by claims that US patients were charged a premium for the same drugs than people in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been paused or scrapped, while major funding commitments have been directed toward projects in the United States.
One official acknowledged that the NHS had to increase expenditure on medicines, noting that its spending on drugs had shrunk as a proportion of its resources over the last ten years.
